MEDNAX, Inc. (NYSE:MD – Get a rating) received a consensus rating of “Hold” by the eleven brokerages that currently cover the company, Market Beat Ratings reports. One investment analyst has assigned the stock a sell rating, seven have issued a hold rating and two have assigned the company a buy rating. The 1-year average price target among analysts who have reported on the stock in the past year is $29.38.
Several research analysts have weighed in on MD shares. TheStreet upgraded MEDNAX from a “b-” to a “c+” rating in a Wednesday, April 13 research report. Credit Suisse Group cut its price target on MEDNAX from $32.00 to $31.00 and set an “outperform” rating on the stock in a Wednesday, Feb. 23 research note. StockNews.com began covering MEDNAX in a research note on Thursday, March 31. They issued a “buy” rating on the stock. To finish, Zacks Investment Research downgraded MEDNAX from a “buy” rating to a “hold” rating and set a price target of $25.00 for the stock. in a research note from Wednesday, April 20.
Shares of MARYLAND opened at $18.52 on Monday. MEDNAX has a 52-week low of $18.46 and a 52-week high of $35.67. The company has a debt ratio of 1.12, a quick ratio of 1.97 and a current ratio of 1.97. The stock has a 50-day simple moving average of $23.22 and a 200-day simple moving average of $25.11. The company has a market capitalization of $1.61 billion, a PE ratio of 17.31, a P/E/G ratio of 1.33 and a beta of 2.06.
MEDNAX (NYSE:MD – Get a rating) last reported quarterly earnings data on Thursday, April 28. The company reported earnings per share (EPS) of $0.33 for the quarter, beating analyst consensus estimates of $0.27 by $0.06. MEDNAX posted a return on equity of 15.76% and a net margin of 4.73%. The company posted revenue of $482.20 million for the quarter, compared to $471.29 million expected by analysts. In the same quarter a year earlier, the company posted EPS of $0.20. The company’s revenues increased by 7.9% compared to the same quarter last year. Equity research analysts expect MEDNAX to post EPS of 1.74 for the current fiscal year.
A number of institutional investors have recently bought and sold shares of MD. Royal Bank of Canada increased its holdings of MEDNAX shares by 198.7% in the 2nd quarter. Royal Bank of Canada now owns 6,192 shares of the company worth $187,000 after buying 4,119 more shares last quarter. Morgan Stanley increased its position in MEDNAX by 19.3% during the 2nd quarter. Morgan Stanley now owns 513,145 shares of the company worth $15,472,000 after acquiring an additional 83,109 shares in the last quarter. State of New Jersey Common Pension Fund D increased its position in MEDNAX shares by 4.1% in the third quarter. New Jersey State Joint Pension Fund D now owns 83,212 shares of the company worth $2,366,000 after buying 3,240 more shares in the last quarter. SG Americas Securities LLC increased its position in MEDNAX shares by 61.7% in the 3rd quarter. SG Americas Securities LLC now owns 7,310 shares of the company worth $208,000 after purchasing an additional 2,790 shares in the last quarter. Finally, the Swiss National Bank increased its position in MEDNAX shares by 0.9% in the 3rd quarter. The Swiss National Bank now owns 171,400 shares of the company worth $4,873,000 after buying an additional 1,500 shares in the last quarter. Institutional investors and hedge funds own 96.99% of the company’s shares.
MEDNAX Company Profile (Get a rating)
MEDNAX, Inc, together with its subsidiaries, provides neonatal, maternal-fetal, pediatric cardiology and other subspecialty pediatric care services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care for babies born prematurely or with complications in specific units of hospitals through neonatal subspecialists, neonatal nurse practitioners, and other pediatric clinicians.
Get news and reviews for MEDNAX Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for MEDNAX and related companies with MarketBeat.com’s FREE daily newsletter.